Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
PIPAC in Multimodal Therapy for Patients With Oligometastatic Peritoneal Gastric Cancer (PIPAC_VEROne)

chemotherapy (1 PIPAC every 2 systemic chemotherapy cycles). Primary endpoint is the Secondary Resectability Rate. Secondary endpoints are: Overall Survival, Progression Free Survival, Disease Free Survival

  • 0 views
  • 04 Oct, 2022
  • 1 location
mULM to Support Breast Cancer Diagnosis and Therapy

The goal of this project is to adapt the super-resolution ultrasound imaging technology motion-model Ultrasound Localization Microscopy (mULM) to clinical application. In this exploratory patient study a scan protocol will be established to subsequently investigate whether mULM allows the assessment of the tumor response to neoadjuvant chemotherapy in participants with …

Accepts healthy volunteers
  • 0 views
  • 04 Oct, 2022
  • 1 location
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.

strategy that reduces the number of chemotherapy cycles in case of early response to immunochemotherapy is not inferior compared to standard therapy at full dose in terms of Progression-Free Survival (PFS

tumor burden
lactate dehydrogenase
remission
follicular lymphoma
r-chop
  • 0 views
  • 20 Oct, 2022
  • 15 locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

patients into post-consolidation treatment groups. On the second part of this study, patients will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim

flow cytometry
methotrexate
leukemia
b-cell acute lymphoblastic leukemia
inotuzumab
  • 56 views
  • 04 Oct, 2022
  • 120 locations
A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

  • 120 views
  • 16 Oct, 2022
  • 77 locations
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE)

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines.

  • 0 views
  • 29 Oct, 2022
  • 6 locations
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

  • 8 views
  • 04 Oct, 2022
  • 61 locations
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not …

medulloblastoma
corticosteroids
primitive neuroectodermal tumor
cyclophosphamide
vincristine
  • 144 views
  • 25 May, 2022
  • 1 location
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC (MASPAC)

The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary tumor embedded between standard chemotherapy cycles for pain control and prevention of pain in patients

pdac
adenocarcinoma
metastatic pancreatic adenocarcinoma
pancreatic adenocarcinoma
cancer chemotherapy
  • 0 views
  • 05 May, 2022
  • 1 location
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

kinase inhibitor (TKI), either Dasatinib or Ponatinib, will be administered in each of the respective chemotherapy cycles. The TKI (either Dasatinib or Ponatinib) administered in a given cycle of

  • 0 views
  • 07 Oct, 2022
  • 1 location